The fact that aglepristone also exerted the same effect in PRA-positive tumours and not in PRB-positive tumours, suggests that the antiproliferative effect of aglepristone in canine mammary carcinoma is probably mediated by PRA. This evidence concerns the gene S100A6 and neoplasm.